GRAL
GRAIL Inc.
$103.67
+$5.85(+5.98%)
52
Overall
60
Value
50
Tech
47
Quality
Market Cap
$2.97B
Volume
489.28K
52W Range
$20.44 - $118.84
Target Price
$115.00
Company Overview
| Mkt Cap | $2.97B | Price | $103.67 |
| Volume | 489.28K | Change | +5.98% |
| P/E Ratio | -1.5 | Open | $97.81 |
| Revenue | $125.6M | Prev Close | $97.82 |
| Net Income | $-2.0B | 52W Range | $20.44 - $118.84 |
| Div Yield | N/A | Target | $115.00 |
| Overall | 52 | Value | 60 |
| Quality | 47 | Technical | 50 |
No chart data available
About GRAIL Inc.
GRAIL, Inc., a commercial-stage healthcare company, focuses on developing technologies for early cancer detection in the United States and internationally. It provides Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company offers development services including support for ongoing clinical studies, pilot testing, research, and therapy development. It also develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Latest News
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and GRAIL Inc (GRAL)
Catie Powers•21 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GRAL | $103.67 | +6.0% | 489.28K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |